TELO Telomir Pharmaceuticals Inc

Price (delayed)

$1.22

Market cap

$83.91M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.91

Enterprise value

$78.87M

Relative Growth: Rel. Growth:
Relative Strength: Rel. Strength:
Relative Valuation: Rel. Valuation:
Relative Profitability: Rel. Profitability: 9

Telomir Pharmaceuticals, Inc. is a pre-clinical stage pharmaceutical company seeking to lead development in several areas, including age-reversal science. Telomir is focused on the development of Telomir-1, a novel small ...

Highlights
The quick ratio has soared by 131% from the previous quarter
The company's net income has surged by 64% YoY and by 36% QoQ
Telomir Pharmaceuticals's EPS has shrunk by 69% YoY

Key stats

What are the main financial stats of TELO

TELO stock price

How has the Telomir Pharmaceuticals stock price performed over time
Intraday
-2.4%
1 week
7.96%
1 month
7.96%
1 year
-19.74%
YTD
-8.27%
QTD
-4.69%

Financial performance

How have Telomir Pharmaceuticals's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$6.09M
Net income
-$5.88M
Gross margin
N/A
Net margin
N/A
The company's net income has surged by 64% YoY and by 36% QoQ
TELO's operating income has soared by 62% year-on-year and by 35% since the previous quarter

Price vs fundamentals

How does TELO's price correlate with its fundamentals

Growth

What is Telomir Pharmaceuticals's growth rate over time

Valuation

What is Telomir Pharmaceuticals stock price valuation
P/E
N/A
P/B
16.67
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Telomir Pharmaceuticals's EPS has shrunk by 69% YoY
The price to book (P/B) is 67% more than the last 4 quarters average of 10.2

Efficiency

How efficient is Telomir Pharmaceuticals business performance
The ROE has soared by 80% YoY
The return on assets has surged by 54% year-on-year

Dividends

What is TELO's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for TELO.

Financial health

How did Telomir Pharmaceuticals financials performed over time
The quick ratio has soared by 131% from the previous quarter
TELO's current ratio has soared by 131% from the previous quarter
Telomir Pharmaceuticals's debt is 97% less than its equity
Telomir Pharmaceuticals's debt has decreased by 33% from the previous quarter
The company's debt to equity fell by 25% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.